Clinical Evaluation of Classical Ayurvedic Formulations Simhanada Guggulu and Brihat Saindhavadi Taila in the Management of Rheumatoid Arthritis (Amavata): A Multicentric Open Label Prospective Study

JOURNAL TITLE: Journal of Research in Ayurvedic Sciences

Author
1. Bharti
2. Madan M Padhi
3. Bhogavalli CS Rao
4. Bhagwan Sharma
5. Valiparambil C Deep
6. Sangeeta Sangvikar
ISSN
2456-5601
DOI
10.5005/jp-journals-10064-0024
Volume
1
Issue
4
Publishing Year
2017
Pages
9
Author Affiliations
    1. Central Ayurveda Research Institute for Neuromuscular & Musculoskeletal Disorders, Cheruthuruthy, Kerala, India
    1. Regional Ayurveda Institute for Fundamental Research, Pune Maharashtra, India
    1. Sawai ManSingh Medical College, Jaipur, Rajasthan, India
    1. Central Ayurveda Research Institute for Cardiovascular Diseases, New Delhi, India
  • Article keywords
    Amavata, Brihat saindhavadi taila, Rheumatoid Arthritis, Simhanada Guggulu

    Abstract

    Introduction: Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory autoimmune disease associated with articular, extra-articular, and systemic effects. Similar symptoms are found in Amavata described in Ayurveda. Simhanada Guggulu and Brihat Saindhavadi Taila are classical formulations that are used commonly in the management of Amavata. Aims and objectives: To assess the clinical efficacy and safety of the classical Ayurvedic formulations Simhanada Guggulu and Brihat Saindhavadi Taila in patients with RA. Materials and methods: A prospective, open label, multicenter study was carried out at two peripheral centers of the Central Council for Research in Ayurvedic Sciences (CCRAS). A total of 111 patients were administered Simhanada Guggulu and Brihat Saindhavadi Taila in the dose of 1.5 gm (3 tablets of 500 mg each) twice daily after food with lukewarm water and local application twice a day respectively, for a period of 12 weeks. Clinical assessment of symptoms, disease activity score-28 (DAS-28), short form 36 (SF-36), and disability index scoring were done at the baseline and at every subsequent visit at an interval of 14 days up to the 12th week and also in the follow-up without medication at the end of the 14th week. Paired sample t-test was used to compare mean change from baseline to 12th and 14th week respectively. Results: At the end of 12 weeks, statistically significant changes in symptoms, DAS 28, SF-36, and disability index score with p-value <0.001 were observed, compared with baseline. No adverse drug reaction (ADR)/adverse events (AEs) were reported during and after the trial. Conclusion: Simhanada Guggulu and Brihat Saindhavadi Taila administered together in the above-mentioned dose were found effective, safe, and tolerable in patients with RA.

    © 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved